Project Grant R21AI202208
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $265K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Emory University $160,448 on March 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and validate mutations in orthopoxviruses that confer resistance to acyclic phosphonates, characterize the biochemical mechanisms of inhibition by and resistance to these compounds, and evaluate combination therapies to prevent resistance emergence. The research responds to the 2022 global mpox...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $235,500 to the University of California Irvine on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R21AI196970. The award funds research on the molecular architecture of the vaccinia virus factory, with emphasis on characterizing protein interactions at the molecular level during virion morphogenesis. The research...
- Federal Project Grant Award Summary New York University School of Medicine received a $466,125 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2027. The award funds research to elucidate the molecular mechanisms of orthopoxvirus entry, specifically examining the critical initial interactions between viral and human cellular proteins...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $1,023,862 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to produce and distribute filarial research reagents through the Filariasis Research Reagent Resource Center (FR3). The award funds three specific aims over a five-year period ending August 31, 2031. Under Aim 1, the recipient will ensure continued provision of high-quality...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $228,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop enzymatic pipelines for the in vitro synthesis of parasitic glycosylphosphatidylinositol (GPI) anchors and GPI-anchored proteins. Parasitic infections affect more than one billion people globally. GPI anchors and GPI-anchored proteins are essential to parasite cell surfaces and...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $149,190 on December 25, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antiviral compounds targeting lenacapavir-resistant HIV. The research will characterize three novel capsid effectors designed to overcome resistance-associated mutations in HIV that render lenacapavir ineffective. The work comprises three aims: biochemical and biophysical assessment of each...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc., $228,000 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize pan-fungal monoclonal antibodies targeting Aspergillus. The award funds research to develop and evaluate a panel of anti-NXT-2 monoclonal antibodies (MABs) as prophylactic, priority, or adjunctive therapies for invasive aspergillosis and other...
- The National Institute of Allergy and Infectious Diseases awarded University of Georgia Research Foundation, Inc. $805,866 on May 12, 2026, to develop and validate advanced predictive models for influenza vaccine responses under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will integrate longitudinally collected data with statistical and machine-learning methods to overcome limitations in current predictive models, which rely solely on static, pre-vaccination...
- The National Institute of Allergy and Infectious Diseases awarded Cincinnati Children's Hospital Medical Center $243,000 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a pseudovirus nanoparticle-based oral mpox vaccine. The recipient will develop pseudovirus nanoparticles displaying major mpoxvirus protective antigens on a norovirus shell nanoparticle platform, administered orally using U-OMP19 as an adjuvant to enhance mucosal immunity and...
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $197,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cross-protective immune mechanisms of combined mRNA and conventional influenza vaccines. The research develops new mRNA vaccine constructs encoding neuraminidase conjugated to a conserved M2E repeat, designed to enhance broad cross-protection against different...